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SUMMARY 
Aldosterone synthase gene (CYP11B2) encodes the key enzyme of adrenal aldosterone 
production. I here generated a stable H295R cell line expressing CYP11B2 5’-flanking 
region/luciferase cDNA chimeric construct that is highly sensitive to angiotensin II 
(AII) and KCl comparing with the transient transfection using the same promoter region. 
I then examined the effects of various AII receptor blockers (ARBs) on CYP11B2 
transcription using the cell line. In the presence of AII, all ARBs suppressed the 
AII-induced CYP11B2 transcription activation. However, telmisartan, but not other 
ARBs, increased CYP11B2 transcription in the absence of AII. Telmisartan increased 
CYP11B2 transcription dose-dependently and maximally at 12 h. Additionally, 
telmisartan was observed to increase CYP11B2 mRNA expression dose-dependently and 
maximally at 12 h. Moreover, telmisartan dose-dependently increased aldosterone 
secretion. Transient transfection experiments using CYP11B2 5’-flanking region 
deletion mutants/Ad5 point mutant indicated that the Ad5 element was responsible for 
the telmisartan effect. Examinations of transcription factors known to bind to the Ad5 
element revealed that telmisartan significantly induced nerve growth factor-induced 
clone B (NGFIB) and Nur-related factor 1 (NURR1) expression maximal at 1 h and 
gradually decreased steroidogenic factor-1 expression. The telmisartan effect on 
CYP11B2 transcription/mRNA expression was abrogated by KN-93, a 
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Ca2+/calmodulin-dependent kinase (CaMK) inhibitor, treatment. Interestingly, the 
telmisartan-induced NURR1 mRNA expression, but not NGFIB mRNA expression, was 
also abrogated by KN-93. Additionally, the over-expression of NURR1 significantly 
augmented the telmisartan-mediated CYP11B2 transcriptional activation. Interestingly, 
the telmisartan-mediated CYP11B2 transcription was not affected by high-dose 
olmesartan treatment. Taken together, telmisartan may stimulate CYP11B2 transcription 
via the CaMK-mediated induction of NURR1 that activate the Ad5 element, and AII 
type 1 receptor may not be involved in the effect. 
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INTRODUCTION 
Hypertension is well known as one of the most important risk factors for the 
progression of atherosclerosis, which may result in the induction of myocardial 
infarction, brain infarction/hemorrhage, and chronic kidney disease. In 2000, the 
number of patients with hypertension in the world is speculated as one-quarter among 
the whole adult population, and is considered to be increasing every year.1) Among 
hypertensive patients, approximately 20~30% are estimated as “resistant hypertension” 
who are above their target blood pressure even in the simultaneous use of 3 
anti-hypertensive drugs in different classes.2) Since the renin-angiotensin-aldosterone 
system (RAAS) is the main humoral pathway that are profoundly involved in the 
etiology of hypertension, anti-hypertensive drugs blocking the RAAS including the 
direct renin inhibitor, angiotensin-converting enzyme inhibitors, angiotensin II (AII) 
receptor blockers (ARBs), and aldosterone blockers have been clinically used so far.3) 
However, in order to prevent the increase of patients with “resistant hypertension,” 
innovation of novel drugs with different mechanism(s) than the pre-existing RAAS 
blockers may possibly be necessary. 
Aldosterone synthase gene (CYP11B2) encodes the key enzyme of adrenal 
aldosterone production that is mainly regulated by AII and potassium, but also by 
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corticotropin (ACTH) and cyclic AMP (cAMP)4), 5). Since aldosterone, in combination 
with sodium, plays an important role in the progression of hypertension and vascular 
damages,6) the innovation of novel drugs that inhibit CYP11B2 transcriptional activation 
may be advantageous for the treatment of “resistant hypertension.” I therefore have 
been examining the drug-mediated transcriptional regulation of the gene by transient 
transfection using human adrenocortical carcinoma H295R cells that are well known to 
secrete aldosterone as well as cortisol,7) and have recently demonstrated that peroxisome 
proliferator-activated receptor (PPAR)-γ agonist thiazolidinediones inhibit both AII- and 
potassium-mediated CYP11B2 transcriptional activation via Ca2+/calmodulin-dependent 
kinase (CaMK) inhibition.7)       
For the screening of novel drugs, it is important to augment the sensitivity of 
CYP11B2 transcriptional level to be able to detect subtle changes. I therefore generated 
a stable H295R cell line expressing CYP11B2 5’-flanking region/luciferase cDNA 
chimeric construct that is highly sensitive to AII and potassium comparing with the 
transient transfection using the same region. In contrast to AII, the effects of ARBs on 
CYP11B2 transcriptional regulation remain uncertain. I therefore examined the effects 
of various ARBs on CYP11B2 transcription using the stable cell line. 
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OBJECTIVE 
My objective in the present study is to generate a stable H295R cell line expressing 
CYP11B2 5’-flanking region/luciferase cDNA chimeric construct that is sensitive 
enough for the future innovation/discovery of novel anti-hypertensive drugs that inhibit 
CYP11B2 transcription. Using the cell line, I also aimed to examine the effects of 
various ARBs on CYP11B2 transcription. 
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EXPERIMENTAL PROCEDURES 
Reagents 
 Telmisartan, human AII, human ACTH, N6-2'-O-Dibutyladenosine-3',5'-cyclic 
monophosphate (dbcAMP), and Src Inhibitor-1 (Src-I1) were purchased from Sigma (St. 
Louis, MO). Olmesartan medoxomil was purchased from Toronto Research Chemicals 
(North York, Canada). Losartan potassium was purchased from LKT Laboratories (St. 
Paul, MN). Valsartan was kindly provided by Novartis Pharma (Basel, Switzerland). 
Hygromycin B was purchased from Nacalai Tesque (Kyoto, Japan). KN-93 and 
Ro-31-8220 was purchased from Calbiochem (Darmstadt, Germany).  
 
Plasmids 
The subcloned chimeric constructs containing the human CYP11B2 genomic 
DNA and luciferase cDNA (pGL3-Basic, Promega, Madison, WI) kindly provided by 
Dr. William E. Rainey (Medical College of Georgia) were used for the transient 
transfection studies: -1521/+2-luc (harboring the CYP11B2 5’-flanking region from 
-1521 to +2 relative to the transcription start site upstream of the luciferase cDNA in 
pGL3-Basic), -747/+2-luc; -135/+2-luc; -106/+2-luc; -65/+2-luc. Ad5 element in 
-1521/+2-luc was mutated from 5’-CTCCAGCCTTGACCTT-3’ to 
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5’-CTCCAGCCTTGAtaTc-3’ (-1521/+2-luc-Ad5-mut)7), 8) using a QuikChange 
site-directed mutagenesis kit (Stratagene, La Jolla, CA). β-galactosidase control plasmid 
in pCMV (pCMV-β-gal) was purchased from Clontech (Palo Alto, CA). Murine nerve 
growth factor-induced clone B (NGFIB) and Nur-related factor 1 (NURR1) cDNAs 
were cloned by PCR from murine pituitary AtT20 cell RNA and subcloned into the 
pcDNA3 expression vector (Invitrogen, Carlsbad, CA) (pcDNA3-NGFIB and 
pcDNA3-NURR1). The newly subcloned chimeric construct containing the human 
CYP11B2 5’-flanking region (-1521 to +2) and luciferase cDNA (pGL4.15, Promega) 
termed pGL4-CYP11B2 was used for the generation of a stable cell line.   
 
Cell Culture/Generation of Stable Cell Line 
H295R cells were grown with 1:1 mixture of DMEM and Ham’s F12 medium 
supplemented with 10% fetal bovine serum (FBS), Insulin-Transferrin-Selenium-G 
Supplements (Invitrogen), 1.25 mg/mL BSA (Sigma), 5.35 μg/mL linoleic acid (Sigma), 
100 U/mL penicillin, 100 µg/mL streptomycin. Cells were cultured in a humidified 
incubator at 37°C with 5% CO2. The stable cell line expressing pGL4-CYP11B2 was 
generated as follows. When H295R cells were grown to 80% confluence, they were 
transfected with pGL4-CYP11B2 using Lipofectamine™ LTX and Plus reagent 
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(Invitrogen) for 96 h according to the manufacturer's instructions. Thereafter, the cells 
were incubated with hygromycin B (200 μg/ml) for the selection, and the stable cell line 
(CYP11B2-H295R) was finally obtained. CYP11B2-H295R cells were grown to 100% 
confluence in either 24- or 96-multiwell plates, and were thereafter exposed to ARB for 
12 h in DMEM supplemented with 1% charcoal/resin treated (stripped) FBS.7) In case 
the cells were co-treated with AII, they were exposed to 100 nmol/L AII for the last 6 h. 
In some experiments, the cells were exposed either to 10.4 mmol/L (16 mEq/L of K+) 
potassium (KCl), 10 μmol/L ACTH, 100 nmol/L AII, or 1 mmol/L dbcAMP for 6 h.  
 
RNA Preparation and Quantitative RT-PCR 
When H295R cells were grown to 100% confluence in 24-multiwell plates, they 
were exposed to telmisartan for 12 h in DMEM supplemented with 1% stripped FBS. 
H295R cell total RNA was extracted with TaKaRa FastPure RNA Kit (Takara Bio, 
Ohtsu, Japan) according to the manufacturer’s instructions. Total RNAs were subjected 
to reverse transcription (RT) reaction using PrimeScript Reverse Transcriptase (Takara 
Bio) with random 6mer and oligo dT primers according to the manufacturer’s 
instructions. Thereafter, obtained templates were used for quantitative real-time PCR 
(95 °C, 3 min for 1 cycle; 95 °C, 15 sec; 60 °C, 10 sec; 72 °C, 20 sec for 40 cycles) with 
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iQ Supermix (for CYP11B2) or iQ SYBR green Supermix (for others) (Bio-Rad, 
Hercules, CA) by DNA Engine thermal cycler attached to Chromo4 detector (Bio-Rad). 
The following primers and TaqMan probe (for CYP11B2) sequences were used: 
CYP11B2 (forward, 5’-GGCAGAGGCAGAGATGCTG-3’, reverse, 
5’-CTTGAGTTAGTGTCTCCACCAGGA-3’, probe, 
5’-CTGCACCACGTGCTGAAGCACT-3’), NGFIB （ forward, 
5’-GGAGTGCACAGAAGAACTTC-3’, reverse, 
5’-GGCTTGGATACAGGGCATCT-3’ ） , NURR1 （ forward, 
5’-TGAAGAGAGACGCGGAGAAC-3’, reverse, 
5’-GAAAGCAATGGGGAGTCCAG-3’ ） , steroidogenic factor-1 (SF-1) (forward, 
5’-AGCAGAAGAAGGCACAGATTCG-3’, reverse, 
5’-CTGGGAGGCAGCACGTAGTC-3’), β-actin (forward, 
5’-CCAACCGCGAGAAGATGACC-3’, reverse, 
5’-CCAGAGGCGTACAGGGATAG-3’). 
 
Measurement of aldosterone concentration 
When H295R cells were grown to confluence in 24-multiwell plates, they were 
exposed to telmisartan for 12 h in DMEM supplemented with 1% stripped FBS. 
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Aldosterone concentrations of the media were thereafter measured by Aldosterone EIA 
Kit (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer's 
instructions. 
 
Transient Transfection/Luciferase Assay 
  When H295R cells were grown to 80% confluence in 24-multiwell plates, they 
were transiently transfected with 200 ng luciferase reporter plasmids and 100 ng 
pCMV-β-gal using Lipofectamine LTX and Plus reagent (Invitrogen) for 48 h according 
to the manufacturer's instructions. In some experiments, expression vector including 
pcDNA3-NGFIB or pcDNA3-NURR1 (200 ng) was also transfected. The media were 
changed to DMEM supplemented with 1% stripped FBS, and the cells were incubated 
with or without telmisartan for 12 h. In some experiments, the cells were exposed either 
to 10.4 mmol/L KCl, 10 μmol/L ACTH, 100 nmol/L AII, or 1 mmol/L dbcAMP for 6 h. 
After appropriated treatments, they were washed with PBS, and the cell extracts were 
prepared using Glo Lysis Buffer (Promega). Luciferase activity was measured using 
Bright-Glo reagents (Promega), and β-galactosidase activity was simultaneously 
measured. Data were normalized by β-galactosidase activity. In case of 
CYP11B2-H295R cells (the stable cell line), only luciferase activity was measured after 
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appropriate treatments.  
 
Statistical Analysis 
All data are presented as mean ± SEM. Statistical analyses were performed with 
ANOVA followed by post hoc Tukey test.  
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RESULTS 
Differential regulation of CYP11B2 transcription between transiently transfected 
H2965R cells and the stable CYP11B2-H295R cells 
I first compared the effects of KCl, ACTH, AII, and dbcAMP on CYP11B2 
transcriptional regulation between transiently transfected H295R cells and the stable 
CYP11B2-H295R cells. In transiently transfected H295R cells, KCl, ACTH, AII, and 
dbcAMP induced 8.5-fold, 1.9-fold, 5.7-fold, and 12.3-fold compared to control, 
respectively (Fig. 1). In contrast, KCl, ACTH, AII, and dbcAMP induced 52.9-fold, 
1.5-fold, 107.9-fold, and 15.6-fold compared to control, respectively in the stable 
CYP11B2-H295R cells (Fig. 1). Therefore, although the effects of ACTH and dbcAMP 
on CYP11B2 transcription were almost identical between both cells, the responsiveness 
to KCl and AII were dramatically augmented in the stable CYP11B2-H295R cells.         
  
Differential effects of ARBs on CYP11B2 transcription in the presence or absence of AII  
I next examined the effects of various ARBs on CYP11B2 transcription either 
in the presence or absence of AII using the stable CYP11B2-H295R cells. As shown in 
Fig. 2A, all ARBs including telmisartan, valsartan, losartan, and olmesartan suppressed 
the AII-induced CYP11B2 transcriptional activation approximately in a dose dependent 
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manner. In contrast, in the absence of AII, telmisartan at 10 μmol/L significantly 
increased CYP11B2 transcription (Fig. 2B). These data indicate that telmisartan, in 
contrast to other ARBs, induces CYP11B2 transcriptional activity in the absence of AII. 
 
Time course/dose-response analyses of the telmisartan effects on the CYP11B2 
transcriptional activation 
I next performed time course and dose-response analyses of the telmisartan 
effects using the stable CYP11B2-H295R cells. As shown in Fig. 3A, telmisartan at 10 
μmol/L induced CYP11B2 transcriptional activation maximal at 12 h. Dose response 
analyses revealed that telmisartan dose-dependently increased CYP11B2 transcriptional 
activity (Fig. 3B).  
 
Stimulatory effects of telmisartan on CYP11B2 mRNA expression/aldosterone secretion 
I next examined the effects of telmisartan on CYP11B2 mRNA expression and 
aldosterone secretion. Time course analyses of CYP11B2 mRNA expression revealed 
that telmisartan at 10 μmol/L increased CYP11B2 mRNA expression maximal at 12 h 
(Fig. 4A) in H295R cells as well as CYP11B2 transcriptional activation (Fig. 3A). As 
shown in Fig. 4B, telmisartan also increased CYP11B2 mRNA expression 
15 
 
dose-dependently in H295R cells as well as CYP11B2 transcriptional activation (Fig. 
3B). Additionally, telmisartan dose-dependently increased aldosterone secretion from 
H295R cells into the media (Fig. 4C). Taken together, telmisartan-induced CYP11B2 
transcriptional activation increases CYP11B2 mRNA expression, which most likely 
results in the increase of aldosterone production/secretion.   
 
Possible involvement of the Ad5 element in the telmisartan-mediated CYP11B2 
transcriptional activation 
I next examined the element responsible for the telmisartan-mediated CYP11B2 
transcriptional activation. As shown in Fig. 5A, the telmisartan effect was observed in 
CYP11B2 5’-flanking region deletion mutants from -1521/+2-luc to -135/+2-luc, but not 
in -106/+2-luc and -65/+2-luc. Since the Ad5 element is known to locate between -129 
and -114,5) I used -1521/+2-luc-Ad5-mut whose Ad5 element was mutated. As shown in 
Fig. 5B, mutation of the element completely abrogated the telmisartan effect. These data 
indicate that telmisartan stimulates CYP11B2 transcription via the Ad5 element. 
 
Effects of telmisartan on mRNA expression of transcription factors involved in the 
CYP11B2 transcription via binding to the Ad5 element 
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I next examined the effects of telmisartan (10 μmol/L) on mRNA expression of 
transcription factors involved in the CYP11B2 transcription via binding to the Ad5 
element using the same RNAs used in Fig. 4A (CYP11B2 mRNA time course analyses). 
Interestingly, telmisartan treatment induced both NGFIB (Fig. 6A) and NURR1 (Fig. 
6B) mRNA expression maximal at 1 h, while gradually decreased SF-1 mRNA 
expression (Fig. 6C). In contrast, mRNA expression of chicken ovalbumin upstream 
promoter transcription factor (COUP-TF), which is also known to bind to the Ad5 
element,5) was not affected (data not shown). Since NGFIB8) and NURR18) are both 
known to trans-activate and SF-18), 9) is known to trans-repress the Ad5 element, the 
increase of NGFIB and NURR1 and the decrease of SF-1 may be involved in the 
telmisartan effect. 
 
Possible involvement of CaMK-mediated NURR1 induction in the telmisartan effect 
Since mRNA expression of NGFIB and NURR1 is known to be induced by AII, 
8) and the induction was reported to be mediated via CaMK, protein kinase C (PKC), 
and Src tyrosine kinase (SRC),10) I next examined the involvement of these kinases in 
the telmisartan effect. When KN-93,7) a CaMK inhibiter, was co-incubated, the effect of 
telmisartan on CYP11B2 transcription was completely abrogated, while a PKC inhibitor 
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Ro-31-822011) and a SRC inhibitor Src-I110) did not affect it (Fig. 7A). I therefore 
examined the involvement of CaMK on the mRNA expression of CYP11B2, NGFIB, 
and NURR1. Since telmisartan induced the mRNA expression of CYP11B2 (Fig. 4A) 
maximally at 12 h, and NGFIB (Fig. 6A) and NURR1 (Fig. 6B) maximally at 1 h, we 
examined the effects of KN-93 at the indicated time points. As shown in Fig 7B, 
CYP11B2 mRNA expression at 12 h was almost completely abrogated by KN-93 
treatment. Although KN-93 treatment did not affect NGFIB mRNA expression at 1 h 
(Fig. 7C), it almost completely abrogated NURR1 mRNA expression at 1 h (Fig. 7D). 
Moreover, over-expression of NURR1, but not NGFIB, further augmented the 
telmisartan-mediated CYP11B2 transcriptional activation (Fig. 7E). These data indicate 
that CaMK-mediated NURR1 induction may be involved in the telmisartan effect. 
 
AII type 1 receptor may not be involved in the telmisartan effect  
In order to examine the possible involvement of AII type 1 receptor (AT1R) in 
the telmisartan effect, I co-incubated the CYP11B2-H295R cells with telmisartan and 
olmesartan (olmesartan was added to the media 3 h prior to telmisartan). As shown in 
Fig. 8, olmesartan did not affect the telmisartan-mediated CYP11B2 transcription even 
at its high doses (Fig. 8). Therefore, AT1R may not be involved in the telmisartan effect. 
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DISCUSSION 
Analyses of CYP11B2 transcription have so far been examined using transient 
transfection experiments. However, since transient transfection is technically 
complicated and normalization by β-galactosidase activity is necessary each time, using 
a stable cell line is favorable. I here have first generated a stable cell line expressing 
CYP11B2 5’-flanking region/luciferase cDNA chimeric plasmid (CYP11B2-H295R 
cells). The cell line has demonstrated a significant responsiveness of CYP11B2 
transcription to both AII (107.9-fold) and potassium (52.9-fold) in contrast to transient 
transfection analyses (AII: 5.7-fold, potassium: 8.5-fold) (Fig. 1). Consistently, in the 
previous studies, responsiveness of CYP11B2 to AII was between 2- to 14.5-fold7), 12-16) 
and that to potassium was between 2.5- to 6.5-fold7), 13), 14), 16) by transient transfection. 
Although the mechanism(s) for the significant responsiveness of CYP11B2 to AII and 
potassium in the stable CYP11B2-H295R cells remains uncertain, the position in the 
chromosomes where the chimeric plasmid was integrated may possibly be important. 
The cells may therefore be useful for the innovation of novel anti-hypertensive 
therapy/drugs that inhibit AII- or potassium-mediated CYP11B2 transcriptional 
activation. 
 I thereafter compared the effects of various ARBs on CYP11B2 transcription 
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using the stable CYP11B2-H295R cells. As expected, all ARBs inhibited the 
AII-mediated CYP11B2 transcriptional activation (Fig. 2A), and the inhibition of 
CYP11B2 transcription may possibly result in the decrease of aldosterone secretion. 
Since aldosterone is well known to induce damages in organs such as brain, heart, and 
kidney,7) the ARB-mediated CYP11B2 transcriptional inhibition may ameliorate these 
organ damages. However, in the absence of AII, telmisartan, but not other ARBs, 
stimulated CYP11B2 transcription (Fig. 2B, Fig. 3) as well as CYP11B2 mRNA 
expression and aldosterone secretion (Fig. 4). These data indicate that careful attention 
is needed for choosing ARBs depending on patient situations such as endogenous AII 
levels. Among ARBs, telmisartan is specific in that it functions as partial agonist of 
PPAR-γ.17) I therefore co-incubated the CYP11B2-H295R cells with telmisartan and 
PPAR-γ antagonist GW9662 (GW9662 was added to the media 30 min prior to 
telmisartan).7) However, GW9662 did not inhibit, but rather slightly stimulated the 
telmisartan-mediated CYP11B2 transcriptional activation (data not shown). This is 
consistent to our previous observation regarding the inhibitory effects of PPAR-γ 
agonist on the AII-mediated CYP11B2 transcriptional activation.7) Taken together, it is 
suggested that PPAR-γ activation may not be involved in the telmisartan effect.  
Transient transfection experiments using CYP11B2 5’-flanking region deletion 
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mutants/Ad5 mutant have revealed that the Ad5 element was responsible for the 
telmisartan-mediated CYP11B2 transcriptional activation (Fig. 5). Examinations of the 
effects of telmisartan on mRNA expression of transcription factors that are known to 
bind to the Ad5 element have shown that telmisartan induced the mRNA expression of 
positively-regulating NGFIB8) and NURR18) at 1 h, while gradually decreased that of 
negatively-regulating SF-18), 9) (Fig. 6). Recently, AII was also demonstrated to induce 
NGFIB and NURR1 mRNA expression rapidly (~1 h) in H295R cells10), 18) as well as in 
mice.19) The AII-mediated effect was demonstrated to be mediated via CaMK, PKC, and 
SRC pathways.10) Since these pathways are known to be involved in the AII-mediated 
CYP11B2 transcriptional activation,5), 20) I next examined the involvement of these 
pathways in the telmisatran effect. The telmisartan-mediated CYP11B2 transcriptional 
activation was completely abrogated by KN-93, a CaMK inhibitor, treatment, but not by 
inhibitors of other kinases (Fig. 7A). Moreover, KN-93 treatment almost completely 
inhibited the mRNA expression of CYP11B2 (Fig. 7B) and NURR1 (Fig. 7D). Since 
NGFIB mRNA expression was not affected by KN-93 treatment (Fig. 7C), and the 
over-expression of NGFIB little affected the telmisartan-mediated CYP11B2 
transcription (Fig. 7E), CaMK-mediated NURR1 induction may possibly be the main 
pathway of the telmisartan effect. Moreover, since I have observed an increase of 
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H295R cell intracellular Ca2+ by telmisarten treatment (data not shown), it is highly 
possible that both AII and telmisartam activate the same pathway from Ca2+induction, 
CaMK activation, through NURR1 induction (Fig. 9).10), 20)  
I also examined the possibility if telmisartan activates AT1R as its partial 
agonist, as telmisartan has a unique “delta lock” structure that is involved in its strong 
affinity to AT1R among ARBs.21) Since olmesartan was demonstrated to have the 
strongest inhibitory effect on the AII-mediated CYP11B2 transcriptional activation (Fig. 
2A), I co-incubated the CYP11B2-H295R cells with telmisartan and olmesartan 
(olmesartan was added to the media 3 h prior to telmisartan). Olmesartan, however, did 
not diminish the telmisartan-mediated CYP11B2 transcriptional activation even at 50 
μmol/L (Fig. 8). Therefore, it is speculated that AT1R activation may not be involved in 
the telmisartan effect. Since telmisartan is specific among ARBs as it contains a 
methylbenzimidazole ring structure, its structural specificity may contribute to the effect. 
Further studies are needed to clarify the whole signaling pathway of the telmisartan 
effect, and their information may give us clues for the innovation of novel 
anti-hypertensive therapy/drugs. 
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CONCLUSION 
I here generated a stable H295R cell line expressing CYP11B2 5’-flanking 
region/luciferase cDNA chimeric construct that is highly sensitive to AII and KCl. 
Using the cell line, I observed that telmisartan, but not other ARBs, induced CYP11B2 
transcriptional activity in the absence of AII. Activation of CaMK as well induction of 
NURR1 may at least be involved in the telmisartan-mediated CYP11B2 transcriptional 
activation. 
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FIGURE LEGENDS 
Figure 1. Effects of KCl, ACTH, AII, and dbcAMP on CYP11B2 transcription. Either 
H295 cells transiently transfected with -1521/+2-luc and pCMV-β-gal or the stable 
CYP11B2-H295R cells were incubated without (control) or with 10.4 mmol/L KCl, 10 
μmol/L ACTH, 100 nmol/L AII, or 1 mmol/L dbcAMP for 6 h. Open columns 
(transient), transiently transfected H295R cells. Closed columns (stable), the stable 
CYP11B2-H295R cells. Data represent mean ± SEM (n = 6), percent control.          
Figure 2. Effects of various ARBs on CYP11B2 transcription. (A) Effects of ARBs in 
the presence of AII. The stable CYP11B2-H295R cells were incubated either without or 
with indicated concentrations (μmol/L) of various ARBs including telmisartan (Tel), 
valsartan (Val), losartan (Los), and olmesartan (Olm) for 12 h. In some experiments, the 
cells were co-treated with AII (100 nmol/L) for the last 6 h. Data represent mean ± SEM 
(n = 6), percent control (the absence of both AII and ARB). (B) Effects of ARBs in the 
absence of AII. The stable CYP11B2-H295R cells were incubated either without or with 
indicated concentrations (μmol/L) of various ARBs including telmisartan (Tel), 
valsartan (Val), losartan (Los), and olmesartan (Olm) for 12 h. Data represent mean ± 
SEM (n = 6), percent control (the absence of ARB). * P < 0.01, vs. control.  
Figure 3. Time course and dose-response analyses of the telmisartan effects. (A) Time 
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course analyses. The stable CYP11B2-H295R cells were incubated with telmisartan (10 
μmol/L) for the indicated times (h). Data represent mean ± SEM (n = 4), percent control 
(time 0). * P < 0.01, vs. 0 h. (B) Dose-response analyses. The stable CYP11B2-H295R 
cells were incubated with telmisartan (12 h) for the indicated concentrations (μmol/L). 
Data represent mean ± SEM (n = 4), percent control (0 μmol/L). * P < 0.01, vs. 0 
μmol/L.     
Figure 4. Effects of telmisartan on CYP11B2 mRNA expression/aldosterone secretion. 
(A) Time course analyses of CYP11B2 mRNA expression. H295R cells were incubated 
with telmisartan (10 μmol/L) for the indicated times. Data represent mean ± SEM (n = 
3), percent control (0 μmol/L). * P < 0.05, vs. 0 h. (B) Dose-response analyses of 
CYP11B2 mRNA expression. H295R cells were incubated with telmisartan (12 h) for 
the indicated concentrations (μmol/L). Data represent mean ± SEM (n = 3), percent 
control (0 μmol/L). * P < 0.01, vs. 0 μmol/L. (C) Dose-response analyses of aldosterone 
secretion into the media. H295R cells were incubated with telmisartan (12 h) for the 
indicated concentrations (μmol/L). Data represent mean ± SEM (n = 4), percent control 
(0 μmol/L). * P < 0.01, vs. 0 μmol/L. 
Figure 5. Effects of 5’-flanking region mutants on the telmisartan-mediated CYP11B2 
transcriptional activation. (A) Effects of CYP11B2 5’-flanking region deletion mutants. 
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Either -1521/+2-luc, -747/+2-luc, -135/+2-luc, -106/+2-luc, -65/+2-luc, or pGL3-Basic 
(control plasmid) was transiently transfected with pCMV-β-gal into H295R cells, and 
the cells were thereafter incubated without (open columns) or with 10 μmol/L (filled 
columns) telmisartan (Tel) for 12 h. Data represent mean ± SEM (n = 4-10), percent 
control (0 μmol/L in -1521/+2-luc). * P < 0.01, vs. 0 μmol/L in -1521/+2-luc. †P < 0.01, 
vs. 0 μmol/L in -747/+2-luc. ¶ P < 0.01, vs. 0 μmol/L in -135/+2-luc. (B) Effects of the 
Ad5 element mutant. Either -1521/+2-luc, -1521/+2-luc-Ad5-mut or pGL3-Basic 
(control plasmid) was transiently transfected with pCMV-β-gal into H295R cells, and 
the cells were thereafter incubated without (open columns) or with 10 μmol/L (filled 
columns) telmisartan (Tel) for 12 h. Data represent mean ± SEM (n = 4), percent control 
(0 μmol/L in -1521/+2-luc). * P < 0.01, vs. 0 μmol/L in -1521/+2-luc.  
Figure 6. Effects of telmisartan on the mRNA expression of transcription factors 
involved in the CYP11B2 transcriptional regulation via binding to the Ad5 element. (A) 
Time course analyses of NGFIB mRNA expression. H295R cells were incubated with 
telmisartan (10 μmol/L) for the indicated times. Data represent mean ± SEM (n = 3), 
percent control (0 μmol/L). * P < 0.05, vs. 0 h. (B) Time course analyses of NURR1 
mRNA expression. H295R cells were incubated with telmisartan (10 μmol/L) for the 
indicated times. Data represent mean ± SEM (n = 3), percent control (0 μmol/L). * P < 
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0.01, vs. 0 h. (C) Time course analyses of SF-1 mRNA expression. H295R cells were 
incubated with telmisartan (10 μmol/L) for the indicated times. Data represent mean ± 
SEM (n = 3), percent control (0 μmol/L). In (A)-(C), used RNAs were identical to those 
used in Fig. 4A.   
Figure 7. Effects of protein kinase inhibitors and NURR1/NGFIB over-expression on 
the telmisartan-mediated effects. (A) Effects of KN-93, Ro-31-8220, and Src-11 on the 
telmisartan-mediated CYP11B2 transcriptional activation. The stable CYP11B2-H295R 
cells were incubated either without or with 10 μmol/L telmisartan (Tel) for 12 h in the 
absence or presence of 5 μmol/L protein kinase inhibitors (the inhibitors were added to 
the media 30 min prior to telmisartan addition). Data represent mean ± SEM (n = 4), 
percent control (in the absence of both inhibitors and telmisartan). * P < 0.05, vs. 10 
μmol/L telmisartan without inhibitors. (B) Effects of KN-93 on the 
telmisartan-mediated CYP11B2 mRNA expression. H295R cells were incubated with 10 
μmol/L telmisartan (Tel) for 12 h in the absence or presence of 5 μmol/L KN-93 (KN-93 
was added to the media 30 min prior to telmisartan addition). Data represent mean ± 
SEM (n = 4), percent control (in the absence of both KN-93 and telmisartan). * P < 0.01, 
vs. 10 μmol/L telmisartan without KN-93. (C) Effects of KN-93 on the 
telmisartan-mediated NGFIB mRNA expression. H295R cells were incubated with 10 
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μmol/L telmisartan (Tel) for 1 h in the absence or presence of 5 μmol/L KN-93 (KN-93 
was added to the media 30 min prior to telmisartan addition). Data represent mean ± 
SEM (n = 4), percent control (in the absence of both KN-93 and telmisartan). (D) 
Effects of KN-93 on the telmisartan-mediated NURR1 mRNA expression. H295R cells 
were incubated with 10 μmol/L telmisartan (Tel) for 1 h in the absence or presence of 5 
μmol/L KN-93 (KN-93 was added to the media 30 min prior to telmisartan addition). 
Data represent mean ± SEM (n = 4), percent control (in the absence of both KN-93 and 
telmisartan). * P < 0.01, vs. 10 μmol/L telmisartan without KN-93. (E) Effects of 
NGFIB/NURR1 over-expression. H295R cells were transfected with either 
-1521/+2-luc and pcDNA3 (control plasmid), -1521/+2-luc and pcDNA3-NGFIB, or 
-1521/+2-luc and pcDNA3-NURR1 with pCMV-β-gal, and were thereafter incubated 
without or with 10 μmol/L telmisartan (Tel) for 12 h. Data represent mean ± SEM (n = 
4), percent control (0 μmol/L in -1521/+2-luc plus pcDNA3). * P < 0.01, vs. 10 μmol/L 
in -1521/+2-luc plus pcDNA3. 
Figure 8. Effects of olmesartan on the telmisartan-mediated CYP11B2 transcriptional 
activation. The stable CYP11B2-H295R cells were incubated either without or with 10 
μmol/L telmisartan (Tel) for 12 h in the absence or presence of indicated concentrations 
(μmol/L) of olmesartan (Olm) (olmesartan was added to the media 3 h prior to 
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telmisartan). Data represent mean ± SEM (n = 4), percent control (in the absence of 
both olmesartan and telmisartan). 
Figure 9. The possible mechanism of the telmisartan-mediated CYP11B2 transcriptional 
activation.   
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